Avalo Therapeutics, Inc. (AVTX) Market Cap & Valuation Ratios
Avalo Therapeutics, Inc. (AVTX) has a market cap of $371.7M and a price-to-sales ratio of 6299.3, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AVTXAvalo Therapeutics, Inc.Follow AVTX — free
—
Price chart with a free account
- Market cap
- 371.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| AVTX | 0.4 | — | — | — | — | -87% | — | -43% |
| AUTL | 0.4 | — | 1.8 | — | — | +292% | -211% | — |
| SPRY | 0.4 | — | 3.0 | — | — | +4% | -185% | -214% |
| TECX | 0.4 | — | — | — | — | — | — | — |
| CCCC | 0.4 | — | 8.5 | — | — | +2% | -319% | -84% |
| MPLT | 0.4 | — | — | — | — | — | — | -88% |
| EDIT | 0.4 | — | 4.5 | — | — | +21% | -161% | — |
| FENC | 0.4 | — | 5.3 | — | — | +78% | -2% | -94% |
| RLMD | 0.3 | — | — | — | -13.2% | — | — | -62% |
| CAPR | 0.3 | — | — | — | — | — | — | -88% |
| ENTA | 0.3 | — | 2.3 | — | -10.9% | +0.7% | -90% | -115% |
| Median of these 10 | — | 3.8 | — | -12.0% | +12% | -173% | -88% |
.
Growth vs. price
each dot a company · hover or tap for valuesAvalo Therapeutics, Inc. — questions
- What is Avalo Therapeutics, Inc.'s market cap?
- $371.7M.
- What is Avalo Therapeutics, Inc.'s price-to-sales ratio?
- 6299.3.
Every figure on this page comes from Avalo Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.